scispace - formally typeset
E

Elmar Jaeckel

Researcher at Hannover Medical School

Publications -  158
Citations -  4566

Elmar Jaeckel is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Autoimmune hepatitis & Medicine. The author has an hindex of 29, co-authored 128 publications receiving 3903 citations. Previous affiliations of Elmar Jaeckel include Harvard University & Hochschule Hannover.

Papers
More filters
Journal ArticleDOI

Treatment of Acute Hepatitis C with Interferon Alfa-2b

TL;DR: Treatment of acute hepatitis C with interferon alfa-2b with treatment during the acute phase could prevent the development of chronic infection.
Journal ArticleDOI

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

TL;DR: In acute HCV infection, early treatment with peginterferon α2b leads to high virological response rates in individuals who are adherent to treatment, and future studies should identify factors predicting spontaneous viral clearance to avoid unnecessary therapy.
Journal ArticleDOI

Antigen-Specific FoxP3-Transduced T-Cells Can Control Established Type 1 Diabetes

TL;DR: It was found that retroviral transduction of polyclonal CD4 T-cells with FoxP3 was not effective in interfering with established type 1 diabetes, and more subtle and more organ-specific regulation might be required to prevent type1 diabetes, as well as to avoid systemic immunosuppression.
Journal ArticleDOI

Thymic selection revisited: how essential is it?

TL;DR: Positive selection and receptor‐instructed lineage commitment represent a hallmark of the thymus and represent an essential feature for the evolutionary fitness of mammalian species.
Journal ArticleDOI

Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor.

TL;DR: Compared with nTregs, A2‐CAR Tregs exhibited superior control of strong allospecific immune responses in vitro and in humanized mouse models, and have great potential for incorporation into clinical trials of Treg‐supported weaning after allogeneic transplantation.